Scarica l'app Stockscreener
1.92
2.13%
0.04
Dopo l'orario di chiusura:
1.85
-0.07
-3.65%
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Ratios Revealed: Decoding Milestone Pharmaceuticals Inc (MIST)’s Financial Health - DWinneX
Milestone Pharmaceuticals (MIST) Awaits FDA Decision on Cardamyst Resubmission - GuruFocus
Milestone Pharmaceuticals Files Response to FDA for Cardamyst Nasal Spray - MarketScreener
Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha
Milestone Pharmaceuticals Submits Response to FDA for CARDAMYST - TipRanks
Milestone Pharmaceuticals submits response to FDA for PSVT drug - Investing.com
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting - The Manila Times
Milestone Pharmaceuticals Submits Response To The FDA's CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting - marketscreener.com
Milestone's CARDAMYST Could Become First Self-Administered PSVT Treatment After FDA Response - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to “Buy” at HC Wainwright - Defense World
Milestone Pharmaceuticals (MIST) Receives Buy Rating from HC Wai - GuruFocus
Milestone Pharmaceuticals (MIST) Receives Buy Rating with $5 Tar - GuruFocus
Milestone Pharmaceuticals (MIST) Receives Buy Rating from HC Wainwright | MIST Stock News - GuruFocus
Northern Trust Corp Purchases 30,772 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals completes US$94.9M initial public offering - McCarthy Tétrault
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Millennium Management LLC - Defense World
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Manila Times
Milestone Pharmaceuticals Executives Set for Key Presentation at Jefferies Healthcare Conference - Stock Titan
Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $17.00 - Defense World
Milestone Payments: Potential Trouble In The Last Mile? - Life Science Leader
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why - Yahoo Finance
Cubist Systematic Strategies LLC Takes $73,000 Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Milestone Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Milestone Pharmaceuticals Reports First Quarter 2025 Financial R - GuruFocus
Milestone Pharmaceuticals Navigates Regulatory Challenges and Financial Updates in Q1 2025 - TipRanks
Milestone Pharmaceuticals (MIST) Aims to Resolve FDA Issues for CARDAMYST | MIST Stock News - GuruFocus
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results - marketscreener.com
Milestone Pharmaceuticals reports Q1 EPS (31c) vs (21c) last year - TipRanks
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone's CARDAMYST Gets FDA Path Forward: Manufacturing Issues Only, $56M Cash Runway Revealed - Stock Titan
Milestone Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - GlobeNewswire
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Monday - Defense World
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - News Heater
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial - GlobeNewswire
MIST’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
What is Milestone Pharmaceuticals Inc (MIST) Stock Return on Shareholders’ Capital? - Sete News
Deeper Dive: Understanding Milestone Pharmaceuticals Inc (MIST) Through its Various Ratios - DWinneX
Stock Market Recap: Milestone Pharmaceuticals Inc (MIST) Concludes at 0.88, a -60.89 Surge/Decline - DWinneX
The Attractiveness of Investing In Milestone Pharmaceuticals Inc (MIST) is Growing - knoxdaily.com
Milestone Pharmaceuticals Inc (MIST)’s stock price range in the last year - uspostnews.com
Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News
Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX
Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com
A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com
Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com
Examining Milestone Pharmaceuticals Inc (MIST) stock is warranted - uspostnews.com
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):